News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Seeking Alpha Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Expands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates Zoetis' coordinated multi-species response to address New World screwworm across both companion animals and …
Sharemaestro market context Price below Trend Line 52 weeks -56.8%Image source: The Motley Fool. DATE Thursday, Aug. 13, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Steve FrankChief Executive Officer - Kristin PeckChief Financial Officer - Wetteny Joseph TAKEAWAYS Revenue -- $2.5 billion, representing a flat result on …
Sharemaestro market context Price below Trend Line 52 weeks -56.8%Zoetis sign at their Canadian By JHVEPhoto Parsippany, New Jersey-based Zoetis Inc. (ZTS) discovers, develops, manufactures, and commercializes medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry. Valued at $30.5 billion by market cap, …
Brown Advisory, an investment management company, released its "Brown Advisory Global Leaders Strategy" for the second quarter of 2026 investor letter. A copy of the letter can be downloaded here. Brown Advisory's Global Leaders Strategy delivered a net return of 4.6% in the second …
Sharemaestro market context Price below Trend Line 52 weeks -56.8%Key Points Interested in Zoetis Inc.? Here are five stocks we like better. Zoetis reported mixed second-quarter results: Revenue was $2.5 billion, flat reported and down 1% organically, while adjusted EPS rose 4% to $1.87 due partly to share repurchases. Weak U.S. companion-animal demand …
Sharemaestro market context Price below Trend Line 52 weeks -56.8%Zoetis (ZTS) stock fell almost 6% after the company cut its full-year guidance, now expecting adjusted diluted earnings per share between US$6.15 and US$6.25 and a mid to high single-digit decline in organic adjusted net income. This guidance cut was largely driven by a …
Zoetis reported flat top-line growth and a 5% decline in earnings year over year for its second quarter, primarily due to an 11% drop in US companion animal revenue. Consequently, the company significantly reduced its revenue and earnings per share guidance. Morningstar has lowered …
Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Zoetis earnings, guidance cut and new CFO/COO appointment grab investor attention Zoetis (ZTS) is …
Zoetis Inc. ZTS used its second-quarter 2026 earnings call to reset expectations for 2026 as weaker veterinary clinic traffic, pet-owner price sensitivity and heavier competition pressured major Companion Animal franchises. CEO Kristin Peck said management is not assuming the market becomes easier soon. The …
Morningstar has lowered its fair value estimate for Zoetis (ZTS) due to increased competition in the animal health industry. Despite this, Zoetis is still considered the leader in the global animal health industry, known for its innovation across a wide range of products and …
Zoetis Inc. Q2 2026 Earnings Call Summary - Moby Strategic Performance Drivers and Market Dynamics Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap …
Zoetis (ZTS) reported $2.47 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 0.3%. EPS of $1.87 for the same period compares to $1.76 a year ago. The reported revenue represents a surprise of -0.95% over the Zacks Consensus …
Zoetis (NYSE:ZTS) Misses Q2 CY2026 Sales Expectations Animal health company Zoetis (NYSE:ZTS) fell short of the market's revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The company's full-year revenue guidance of $9.22 billion at the midpoint came in …
Zoetis Inc. (NYSE: ZTS) reported Q2 adjusted earnings of $1.87 per share, beating consensus, but sales of $2.468 billion missed estimates, showing flat year-over-year revenue. The company noted softer demand in the companion animal market due to lower clinic visits and pet owner price …
Zoetis (ZTS) came out with quarterly earnings of $1.87 per share, beating the Zacks Consensus Estimate of $1.84 per share. This compares to earnings of $1.76 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings …
Saccaro's Appointment is Effective August 17, 2026; Wetteny Joseph to Serve as a Special Advisor to the CEO on Financial Matters Until Early 2027 PARSIPPANY, N.J., August 06, 2026--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) today announced the appointment of James (Jay) Saccaro as Executive Vice …
Revenue Flat at $2.5 Billion and Net Income of $691 Million, or $1.65 per Diluted Share, Decreasing 5% and Increasing 1%, Respectively, on a Reported Basis Adjusted Net Income of $781 Million, or Adjusted Diluted EPS of $1.87 Revenue and Adjusted Net Income Declined …
Recently, investor Michael Burry increased his position in Zoetis, as the company works through competitive pressures and safety concerns around some companion animal osteoarthritis products while advancing 12 pipeline candidates targeting unmet medical needs. Zoetis has also rolled out new osteoarthritis therapies in Canada …
Zoetis sign at their Canadian By JHVEPhoto Animal healthcare company Zoetis (ZTS) faces headwinds from companion animal product sales due to a competitive landscape, primarily from its key dermatology franchise and Simparica Trio. Moreover, Zoetis' Convenia and Cerenia brands face heightened competition from generic …
Diamond Hill Capital, a First Eagle Investment Management company, issued its Q2 2026 investor letter for its "Large Cap Strategy". A copy of the letter is available to download here. The Strategy returned 3.42% net of fees, trailing the Russell 1000 Value Index's 13.87% …
This article provides a revenue breakdown for Zoetis, Inc. Class A (MUN:ZOE), highlighting its top-performing segment and geographical contributions. In the last fiscal year, the company generated €8.06 billion in revenue, with the Parasiticides segment contributing €1.99 billion and the United States accounting for …
Search by ticker symbol or company name and select a result to open its chart.